Ventricular assist system available for destination therapy
- HeartMate II offers small size, applicability to more patients. Raible, Eric // Cardiology Today;Jun2008, Vol. 11 Issue 6, p24
The article evaluates the HeartMate II LV assist system from Thoratec Corporation.
- HeartMate II approval offers heart therapy for women, small men. Yoffee, Lynn // Biomedical Business & Technology;May2008, Vol. 31 Issue 5, p34
The article offers information on the HeartMate II Left Ventricular Assist System (LVAS) from Thoratec.
- FDA. // Materials Management in Health Care;Dec2002, Vol. 11 Issue 12, p6
Reports the approval received by Thoratec Corp. to market the HeartMate pump for patients with end-stage congestive heart failure not qualified for a heart transplant in Pleasanton, California.
- Financings roundup. // Medical Device Daily;11/8/2011, Vol. 15 Issue 214, p4
The article reports on the authorization by Thoratec's board of the repurchase of an additional 50 million U.S. dollars of its common stock in 2012.
- Stocks Open In Upward Drift; Thoratec Tanks On Study Results. ALAN R. ELLIOTT // Investors Business Daily;11/29/2013, p00
Stocks opened November's final trading session Friday on a quiet up note, although leaders showed some early volatile action.
- Cardio Stocks Shock To Life. Investor's Business Daily // Investors Business Daily;7/27/2015, pA01
7 The cardiology device
- Deals roundup. // Medical Device Daily;8/5/2011, Vol. 15 Issue 146, p8
The article reports on the acquisition by Thoratec of the medical business of Levitronix.
- Thoratec works with WiTricity for energy transfer technology. // Medical Device Daily;5/12/2011, Vol. 15 Issue 92, p4
The article offers information on Thoratec, a company that makes devices for circulatory support of failing hearts, and its technology development agreement with WiTricity relating to the WiTricity's proprietary wireless resonant energy transfer technology and its possible applications in...
- Financings roundup. // Medical Device Daily;2/16/2011, Vol. 15 Issue 32, p7
This article reports that the board of Thoratec has authorized the repurchase of up to 100 million U.S. dollars in stock in 2012.